Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter January 7, 2022

Antibody-dependent enhancement of virus infection and disease: implications in COVID-19

  • Ajay Kumar Shukla and Saurav Misra EMAIL logo

Abstract

Antibody-dependent enhancement (ADE) can be seen in a variety of viruses. It has a deleterious impact on antibody treatment of viral infection. This effect was first discovered in the dengue virus, and it has since been discovered in the coronavirus. Over 213 million people have been affected by the rapid spread of the newly emerging coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19). The new coronavirus offers a significant threat and has sparked widespread concern. ADE in dengue virus and other viruses are discussed with possible effect on COVID-19 treatment and vaccine development will need to consider this phenomenon to ensure it is mitigated and avoided altogether. In these case scenarios, the role of ADE and its clinical consequences remains to be explored for this newly detected virus.


Corresponding author: Dr. Saurav Misra, Senior Resident, Department of Pharmacology, AIIMS Bhopal, Bhopal, India, E-mail:

  1. Research funding: None.

  2. Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  3. Competing interests: Yes, all authors state that there is no conflict of interest.

  4. Informed consent: Not required.

  5. Ethical approval: No requirement of ethical approval.

References

1. Tirado, SMC, Yoon, K-J. Antibody-dependent enhancement of virus infection and disease. Viral Immunol 2003;16:69–86. 10.1089/088282403763635465. 12725690.10.1089/088282403763635465Search in Google Scholar PubMed

2. Willey, S, Aasa-Chapman, MMI, O’Farrell, S, Pellegrino, P, Williams, I, Weiss, RA, et al.. Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infection. Retrovirology 2011;8:16. https://doi.org/10.1186/1742-4690-8-16.Search in Google Scholar PubMed PubMed Central

3. Hawkes, RA, Lafferty, KJ. The enhancement of virus infectivity by antibody. Virology 1967;33:250–61. https://doi.org/10.1016/0042-6822(67)90144-4.Search in Google Scholar PubMed

4. Kulkarni, R. Antibody-dependent enhancement of viral infections. Dynam Immune Activation Viral Dis 2019;9–41. https://doi.org/10.1007/978-981-15-1045-8_2. PMC7119964.10.1007/978-981-15-1045-8_2Search in Google Scholar PubMed

5. Diamond, MS, Pierson, TC. Molecular insight into dengue virus pathogenesis and its Implications for disease control. Cell 2015;162:488–92. https://doi.org/10.1016/j.cell.2015.07.005.Search in Google Scholar PubMed PubMed Central

6. Halstead, SB. Dengue antibody-dependent enhancement: knowns and unknowns. Microbiol Spectr 2014;2:1–18. https://doi.org/10.1128/microbiolspec.aid-0022-2014.Search in Google Scholar

7. Meyer, B, Drosten, C, Müller, MA. Serological assays for emerging coronaviruses: challenges and pitfalls. Virus Res 2014;194:175–83. https://doi.org/10.1016/j.virusres.2014.03.018.Search in Google Scholar PubMed PubMed Central

8. Wen, J, Cheng, Y, Ling, R, Dai, Y, Huang, B, Huang, W, et al.. Antibody-dependent enhancement of coronavirus. Int J Infect Dis 2020;100:483–9. https://doi.org/10.1016/j.ijid.2020.09.015.Search in Google Scholar PubMed PubMed Central

9. Prescott, J, Falzarano, D, de Wit, E, Hardcastle, K, Feldmann, F, Haddock, E, et al.. Pathogenicity and viral shedding of MERS-CoV in immunocompromised rhesus macaques. Front Immunol 2018;12:205. https://doi.org/10.3389/fimmu.2018.00205.Search in Google Scholar PubMed PubMed Central

10. Kam, YW, Kien, F, Roberts, A, Cheung, YC, Lamirande, EW, Vogel, L, et al.. Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro. Vaccine 2007;25:729–40. https://doi.org/10.1016/j.vaccine.2006.08.011.Search in Google Scholar PubMed PubMed Central

11. Yip, MS, Leung, NH, Cheung, CY, Li, PH, Lee, HH, Daëron, M, et al.. Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus. Virol J 2014;11:82. https://doi.org/10.1186/1743-422x-11-82.Search in Google Scholar

12. Yip, MS, Leung, HL, Li, PH, Cheung, CY, Dutry, I, Li, D, et al.. Antibody-dependent enhancement of SARS coronavirus infection and its role in the pathogenesis of SARS. Hong Kong Med J 2016;22(3 Suppl 4):25–31.10.1186/1753-6561-5-S1-P80Search in Google Scholar

13. Luo, F, Liao, FL, Wang, H, Tang, HB, Yang, ZQ, Hou, W. Evaluation of antibody-dependent enhancement of SARS-CoV infection in rhesus macaques immunized with an inactivated SARS-CoV vaccine. Virol Sin 2018;33:201–4. https://doi.org/10.1007/s12250-018-0009-2.Search in Google Scholar PubMed PubMed Central

14. Wang, SF, Tseng, SP, Yen, CH, Yang, JY, Tsao, CH, Shen, CW, et al.. Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins. Biochem Biophys Res Commun 2014;451:208–14. https://doi.org/10.1016/j.bbrc.2014.07.090.Search in Google Scholar PubMed PubMed Central

15. Vennema, H, de Groot, RJ, Harbour, DA, Dalderup, M, Gruffydd-Jones, T, Horzinek, MC, et al.. Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization. J Virol 1990;64:1407–9. https://doi.org/10.1128/jvi.64.3.1407-1409.1990.Search in Google Scholar PubMed PubMed Central

16. Sanyaolu, A, Okorie, C, Marinkovic, A, Haider, N, Abbasi, AF, Jaferi, U, et al.. The emerging SARS-CoV-2 variants of concern. Ther Adv Infect Dis 2021;8:20499361211024372. https://doi.org/10.1177/20499361211024372.Search in Google Scholar PubMed PubMed Central

Received: 2021-08-27
Accepted: 2021-12-20
Published Online: 2022-01-07

© 2022 Walter de Gruyter GmbH, Berlin/Boston

Downloaded on 5.3.2024 from https://www.degruyter.com/document/doi/10.1515/jbcpp-2021-0264/html
Scroll to top button